COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with severe COVID-19. Several of the proinflammatory cytokines involved in the pathogenesis of COVID-19 infection recruit a distinct intracellular signaling pathway mediated by JAKs. Consequently, JAK inhibitors, including baricitinib, pacritinib, ruxolitinib, and tofacitinib, may represent an effective therapeutic strategy for controlling the JAK to treat COVID-19. This study indicates the mechanism of cytokine storm and JAK/STAT pathway in COVID-19 as well as the medications used for JAK/STAT inhibitors..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Frontiers in Medicine - 9(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mansoor Khaledi [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Baricitinib |
|---|
| doi: |
10.3389/fmed.2022.961027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ024177857 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ024177857 | ||
| 003 | DE-627 | ||
| 005 | 20230307072915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2022.961027 |2 doi | |
| 035 | |a (DE-627)DOAJ024177857 | ||
| 035 | |a (DE-599)DOAJ3fdc51d375f24f8aa869a960cd9d96e2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Mansoor Khaledi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with severe COVID-19. Several of the proinflammatory cytokines involved in the pathogenesis of COVID-19 infection recruit a distinct intracellular signaling pathway mediated by JAKs. Consequently, JAK inhibitors, including baricitinib, pacritinib, ruxolitinib, and tofacitinib, may represent an effective therapeutic strategy for controlling the JAK to treat COVID-19. This study indicates the mechanism of cytokine storm and JAK/STAT pathway in COVID-19 as well as the medications used for JAK/STAT inhibitors. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a JAK inhibitors | |
| 650 | 4 | |a baricitinib | |
| 650 | 4 | |a pacritinib | |
| 650 | 4 | |a ruxolitinib | |
| 650 | 4 | |a tofacitinib | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Fatemeh Sameni |e verfasserin |4 aut | |
| 700 | 0 | |a Sheida Yahyazade |e verfasserin |4 aut | |
| 700 | 0 | |a Maedeh Radandish |e verfasserin |4 aut | |
| 700 | 0 | |a Parviz Owlia |e verfasserin |4 aut | |
| 700 | 0 | |a Nader Bagheri |e verfasserin |4 aut | |
| 700 | 0 | |a Hamed Afkhami |e verfasserin |4 aut | |
| 700 | 0 | |a Mohamad Mahjoor |e verfasserin |4 aut | |
| 700 | 0 | |a Zahra Esmaelpour |e verfasserin |4 aut | |
| 700 | 0 | |a Maryam Kohansal |e verfasserin |4 aut | |
| 700 | 0 | |a Farzad Aghaei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Medicine |d Frontiers Media S.A., 2014 |g 9(2022) |w (DE-627)DOAJ000022292 |x 2296858X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fmed.2022.961027 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3fdc51d375f24f8aa869a960cd9d96e2 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fmed.2022.961027/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2296-858X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 | ||